IMPROVING COVID-19 VACCINATION UPTAKE IN HIV POSITIVE PREGNANT WOMEN IN NIGERIA

提高尼日利亚 HIV 阳性孕妇的 COVID-19 疫苗接种率

• 批准号: 10619475
• 负责人: Alash'le G. Abimiku
• 金额: $ 14.22万
• 依托单位: INSTITUTE OF HUMAN VIROLOGY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10619475
• 关键词: 2019-nCoV; Address; Adult; Affect; Africa; African; Birth History; COVID-19; COVID-19 pandemic; COVID-19 vaccination; COVID-19 vaccine; Cohort Studies; Country; Data; Decision Making; Developing Countries; Education; Educational Materials; Focus Groups; Funding; Future; Grant; Guidelines; HIV; HIV Infections; HIV Seropositivity; HIV-1; Healthcare Systems; Hospitals; Immune response; Improve Access; Infant; Infection; Infrastructure; Interviewer; Literature; Mothers; Natural History; Nigeria; Nigerian; Normalcy; Passive Transfer of Immunity; Persons; Policies; Policy Maker; Population; Pregnant Women; Preparation; Prevalence; Prevention; Public Health; Questionnaires; Research; Resources; SARS-CoV-2 antibody; Shapes; Soldier; Structure; Testing; Time; Travel; United States National Institutes of Health; Vaccinated; Vaccination; Vaccines; Vulnerable Populations; Woman; base; design; experience; fighting; improved; insight; pandemic disease; population based; pregnant; prospective; response; social; social culture; success; unvaccinated; vaccine acceptance; vaccine access; vaccine hesitancy

A. Project Summary/Abstract With the current global devastation and loss of lives, livelihood, and share suffering as a result of the COVID-19 pandemic, especially with the weak health care systems and limited resources in Africa, there is need to conduct research that will provide valuable information on treatment and prevention options and to understand the peculiarities of different populations as they respond. The effective COVID-19 vaccines have been largely instrumental to success in fighting the pandemic in the last 18 months. While most countries in the developed world have vaccinated over 70% of their population, only 21 African countries have fully vaccinated between 10% and 19% of their populations. Nigeria has only vaccinated 7.2% of its adult population and boosted only 0.4% and there is currently no data of vaccination in pregnant women or HIV infected persons. Even with the improved access of vaccines to Africa, vaccine hesitancy continues to limit the ability to improve vaccine coverage in these countries. Our ongoing NIH funded BEAMING grant (5U01HD094658) situated at a tertiary hospital where we have conducted research for over 20 years and including two prospective natural history birth cohort studies in HIV is uniquely placed to rapidly provide information for the first time from this part of the world that is this vulnerable population. This supplemental submission builds on the BEAMING experience and infrastructure to address research questions of great public health importance on social and culture norms that could explain vaccine hesitancy in this vulnerable population. We plan to use the information to develop culturally and socially acceptable educational materials and sessions that target drivers of vaccine hesitancy in HIV pregnant women and their matched uninfected pregnant controls in Nigeria, with the objective of re-shaping policies and strategies towards improved COVID-19 vaccines uptake in preparation for other waves of SARS COV-2 or future pandemics through three specific aims. Aim 1 will document social and cultural reasons for COVID-19 vaccine hesitancy among pregnant women in Nigeria and whether HIV infection creates an additional layer of burden. Aim 2 will develop strategies and educational materials to improve COVID-19 vaccine hesitancy and coverage in this population based on responses obtained from Aim 1. Aim 3 will document for the presence of anti- SARS-CoV-2 antibodies in infected pregnant women with or without HIV-1 infection; and if possible, the presence of anti- SARS-CoV-2 passively transferred antibodies in their infants.

A.项目摘要/摘要 由于当前的全球毁灭​​和生命丧失，生计和分享痛苦 19009年大流行，尤其是在较弱的医疗保健系统和有限的资源 非洲，需要进行研究，以提供有关治疗和 预防选择，并在反应时了解不同人群的特殊性。 有效的Covid-19疫苗在很大程度上对与之抗争 过去18个月大流行。虽然发达国家的大多数国家已经接种疫苗 超过70％的人口，只有21个非洲国家已经完全接种了10％至 他们的人口中有19％。尼日利亚仅接种了其成人人口的7.2％，并增加了 仅0.4％，目前尚无孕妇或HIV感染的疫苗接种数据 人。即使疫苗可以改善非洲的访问，疫苗的犹豫仍在继续限制 改善这些国家的疫苗覆盖范围的能力。我们正在进行的NIH资助的笑容 格兰特（5U01HD094658）位于三级医院，我们已经进行了研究 超过20年，包括两项前瞻性自然历史出生队列研究， 独特地放置在世界这一地区首次快速提供信息 那就是这个脆弱的人群。这种补充提交的束缚 经验和基础设施解决有关公共健康重要性的研究问题 关于可以解释疫苗犹豫不决的社会和文化规范。 我们计划使用这些信息来发展文化和社会可接受的教育 针对艾滋病毒孕妇疫苗犹豫的驱动因素的材料和会议 尼日利亚匹配未​​感染的怀孕对照，目的是重新制定政策和 改善COVID-19疫苗吸收的策略，以准备其他SARS的浪潮 COV-2或未来大流程通过三个特定目标。 AIM 1将记录社会和文化 尼日利亚孕妇疫苗犹豫不决的疫苗犹豫不决的原因以及艾滋病毒是否 感染会产生额外的负担。 AIM 2将制定策略和教育 改善COVID-19-19疫苗犹豫不决和覆盖范围的材料 从AIM 1获得的响应。AIM3将记录到存在抗SARS-COV-2 感染或没有HIV-1感染的感染孕妇的抗体；如果可能的话， 抗SARS-COV-2的存在在婴儿中被动转移抗体。